Quick Answer
Unicycive Therapeutics, Inc. reported Total Assets of $49.14 million for the year ending 2025.
- Unicycive Therapeutics, Inc. showed an increase of +55.2% in Total Assets from 2024 to 2025.
- This data is from Unicycive Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $913.0 thousand | Q3 2021: $19.78 million | Q1 2022: $15.76 million | Q2 2022: $12.82 million | Q3 2022: $10.18 million | Q1 2023: $27.20 million | Q2 2023: $22.88 million | Q3 2023: $19.44 million | Q1 2024: $52.39 million | Q2 2024: $44.70 million | Q3 2024: $38.57 million | Q1 2025: $27.95 million | Q2 2025: $30.00 million | Q3 2025: $50.61 million.
- Over the full 6 years of available data (2020 to 2025), Unicycive Therapeutics, Inc.'s Total Assets has grown by 23,985.8%.
- Historical annual values: Fiscal year 2025: $49.14 million | Fiscal year 2024: $31.67 million | Fiscal year 2023: $14.19 million | Fiscal year 2022: $2.82 million | Fiscal year 2021: $18.74 million | Fiscal year 2020: $204.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: